CD8A and cancer: In spite of the significant reduction of circulating effectors such as CD3+CD8+ and CD3+CD4+ T cells, B and NK cells, in the present preclinical study we observed a synergy between chemotherapeutics and the CI anti-PD-L1 in two immune-competent models of cancer, namely local and metastatic triple negative BC and B cell lymphoma.